pharma news today obesity glp-1 Poll: 1 in 8 Adults Say They Are Currently Taking a Drug for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford FDA Approves Foundayo, the First

speaking fees from Liva-Nova, Johnson and Johnson (Janssen)

Using BPC-157 for IBS If youre considering BPC-157 peptide therapy as a treatment option for IBS, here are some key points to consider: Consult with a Healthcare Professional Before starting BPC-157, its essential to consult with a healthcare provider experienced in peptide therapy

Its likely that calories from saturated fat will be consumed from other sources as well, such as breakfast meats, processed foods, and additional cooking oils used later in the day

Namely: No longer covering GLP-1s for weight loss : Several insurers have made the choice to stop providing coverage for these drugs when used specifically for weight loss, while still covering them for other uses like diabetes